{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yager J"],"funding":["NIMH NIH HHS"],"pagination":["840-846"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9910104"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["38(11)"],"pubmed_abstract":["The transgender community has expressed concerns regarding drug-drug interactions between HIV-pre-exposure prophylaxis (PrEP) and gender-affirming hormones. In this study, we evaluated emtricitabine (F, FTC)/tenofovir (TFV) disoporoxil fumarate (TDF) pharmacokinetics (PK) among adolescent and young adult transgender persons receiving gender-affirming hormone therapy (GAHT). This was a prospective, observational study among transgender women (TW) and men (TM) without HIV, 15-24 years of age, receiving GAHT (estradiol with/without spironolactone, or testosterone). Participants received 1 month of directly observed daily F/TDF. Weekly convenience blood samples were collected for plasma TFV and FTC, and intracellular TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in peripheral blood mo"],"journal":["AIDS research and human retroviruses"],"pubmed_title":["Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones."],"pmcid":["PMC9910104"],"funding_grant_id":["R01 MH114753","P30 MH058107"],"pubmed_authors":["Glenny C","Brothers J","Brooks KM","Anderson PL","Hosek S","Landovitz R","Reirden D","Malhotra M","Yager J","Mulligan K"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.","description":"The transgender community has expressed concerns regarding drug-drug interactions between HIV-pre-exposure prophylaxis (PrEP) and gender-affirming hormones. In this study, we evaluated emtricitabine (F, FTC)/tenofovir (TFV) disoporoxil fumarate (TDF) pharmacokinetics (PK) among adolescent and young adult transgender persons receiving gender-affirming hormone therapy (GAHT). This was a prospective, observational study among transgender women (TW) and men (TM) without HIV, 15-24 years of age, receiving GAHT (estradiol with/without spironolactone, or testosterone). Participants received 1 month of directly observed daily F/TDF. Weekly convenience blood samples were collected for plasma TFV and FTC, and intracellular TFV-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP) in peripheral blood mo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-29T02:08:36.24Z","creation":"2025-04-07T00:43:23.612Z"},"accession":"S-EPMC9910104","cross_references":{"pubmed":["35943868"],"doi":["10.1089/AID.2022.0043","10.1089/aid.2022.0043"]}}